Foreign pharmaceutical giants who want to continue their work in Ukraine have six months to make their choices and cut off their relations with the Russian Federation, where their production is intensified, or enter Ukraine with a complete ban. This is stated in an article published on the UNIAN agency website. In the material devoted to the analysis of the Law “On Medicines” of Ukraine, it also states that the interests of patients will not be harmed in any way.
After all, although this document allows the prohibition of drugs manufactured in the Russian Federation and Belarus, or by foreign companies engaged in direct or indirect activities in the production of drugs in Russia or Belarus, exceptions are made for some drugs. First of all, the availability of illegal drug analogues on the Ukrainian market should be ensured.
“At the same time, manufacturers of these analogues must confirm in writing to the Ministry of Health that they are ready to meet 100% of the country’s need for a particular drug. In the absence of such letters, the drug must have at least three analogues,” the article states.
In addition, the following categories of drugs cannot be prohibited: biological and immunobiological; original (innovative); for the treatment of rare (orphan) diseases; form of release and dosage drugs without generic substitutes in Ukraine; essential drugs for HIV/AIDS; drugs for which a contract valid before February 24, 2022 has been concluded for the purchase of budget funds.
If foreign manufacturers do not want to reduce their capacity in Russia and Belarus, they risk losing the Ukrainian consumer, which means for them to lose 6% of the entire pharmaceutical market.
So, will Ukrainian players in the pharmaceutical market benefit from this? Minimal, because the volume of problems faced by the industry during the war cannot be offset by the seizure of just a few drugs.
“In monetary terms, the volume of pharmaceutical sales fell by about a quarter. We lost millions of consumers who were part of the market in the occupied territories, logistics suffered greatly. Thanks, thanks to the 1-2% that we can compensate for. The head of one of the Ukrainian pharmaceutical companies told the publication, by law, it is a drop in the ocean,” he said, adding that any belief in “targeted screening of the market” is not based on fact-checking. They are not harmed in any way. And foreign manufacturers can at any moment stop working on the Russian market and return to Ukraine” – the publication says.
Source: Focus
John Holton is a seasoned author and journalist, known for his expertise in economics. He currently works as a writer at 24 news breaker, where he provides readers with in-depth analysis and commentary on the latest economic developments. With a background in finance and a talent for explaining complex economic concepts in a clear and accessible way, John’s writing is a must-read for anyone interested in staying informed about the economy.